ATE443713T1 - Makrozyklische peptide mit wirkung gegen das hepatitis-c-virus - Google Patents

Makrozyklische peptide mit wirkung gegen das hepatitis-c-virus

Info

Publication number: ATE443713T1
Authority: AT; Austria
Prior art keywords: alkyl; virus; active against; against hepatitis; macrocyclic peptides
Prior art date: 2002-10-25

Application number

AT03809217T

Other languages

English (en)

Inventor

Montse Llinas-Brunet

Murray Bailey

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-10-25

Filing date

2003-10-20

Publication date

2009-10-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32180514&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE443713(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-10-20 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2009-10-15 Application granted granted Critical

2009-10-15 Publication of ATE443713T1 publication Critical patent/ATE443713T1/de

Links

241000711549 Hepacivirus C Species 0.000 title 1
102000004196 processed proteins & peptides Human genes 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 title 1
-1 O-(C1-6)alkyl Chemical group 0.000 abstract 2
125000003368 amide group Chemical group 0.000 abstract 2
125000004093 cyano group Chemical group *C#N 0.000 abstract 2
125000000753 cycloalkyl group Chemical group 0.000 abstract 2
125000001475 halogen functional group Chemical group 0.000 abstract 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
101800001838 Serine protease/helicase NS3 Proteins 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Virology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Communicable Diseases (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)

AT03809217T 2002-10-25 2003-10-20 Makrozyklische peptide mit wirkung gegen das hepatitis-c-virus ATE443713T1 (de)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US42141402P	2002-10-25	2002-10-25
US43382002P	2002-12-16	2002-12-16
US44276803P	2003-01-27	2003-01-27
PCT/CA2003/001604 WO2004037855A1 (en)	2002-10-25	2003-10-20	Macrocyclic peptides active against the hepatitis c virus

Publications (1)

Publication Number	Publication Date
ATE443713T1 true ATE443713T1 (de)	2009-10-15

Family

ID=32180514

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03809217T ATE443713T1 (de)	2002-10-25	2003-10-20	Makrozyklische peptide mit wirkung gegen das hepatitis-c-virus

Country Status (9)

Country	Link
US (2)	US20050075279A1 (de)
EP (1)	EP1558632B1 (de)
JP (1)	JP4398424B2 (de)
AT (1)	ATE443713T1 (de)
AU (1)	AU2003275826A1 (de)
CA (1)	CA2498572C (de)
DE (1)	DE60329408D1 (de)
ES (1)	ES2330932T3 (de)
WO (1)	WO2004037855A1 (de)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ335276A (en)	1996-10-18	2000-09-29	Vertex Pharma	Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease
SV2003000617A (es) *	2000-08-31	2003-01-13	Lilly Co Eli	Inhibidores de la proteasa peptidomimetica ref. x-14912m
US6867185B2 (en) *	2001-12-20	2005-03-15	Bristol-Myers Squibb Company	Inhibitors of hepatitis C virus
US7119072B2 (en) *	2002-01-30	2006-10-10	Boehringer Ingelheim (Canada) Ltd.	Macrocyclic peptides active against the hepatitis C virus
MY140680A (en)	2002-05-20	2010-01-15	Bristol Myers Squibb Co	Hepatitis c virus inhibitors
US20050075279A1 (en) *	2002-10-25	2005-04-07	Boehringer Ingelheim International Gmbh	Macrocyclic peptides active against the hepatitis C virus
US7176208B2 (en) *	2003-04-18	2007-02-13	Enanta Pharmaceuticals, Inc.	Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
MY148123A (en)	2003-09-05	2013-02-28	Vertex Pharma	Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
EP1673385B1 (de) *	2003-09-22	2011-03-02	Boehringer Ingelheim International GmbH	Makrozyklische peptide mit wirkung gegen das hepatitis-c-virus
NZ546663A (en)	2003-10-10	2010-01-29	Vertex Pharma	Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US7491794B2 (en) *	2003-10-14	2009-02-17	Intermune, Inc.	Macrocyclic compounds as inhibitors of viral replication
DE602004019973D1 (de) *	2003-12-08	2009-04-23	Boehringer Ingelheim Int	Abtrennung von ruthenium-nebenprodukten durch behandlung mit überkritischen flüssigkeiten
WO2005070955A1 (en) *	2004-01-21	2005-08-04	Boehringer Ingelheim International Gmbh	Macrocyclic peptides active against the hepatitis c virus
ES2336009T3 (es)	2004-01-30	2010-04-07	Medivir Ab	Inhibidores de la ns-3 serina proteasa del vhc.
CN1922174A (zh)	2004-02-20	2007-02-28	贝林格尔·英格海姆国际有限公司	病毒聚合酶抑制剂
ES2338666T3 (es)	2004-03-15	2010-05-11	Boehringer Ingelheim International Gmbh	Procedimiento para la preparacion de dipeptidos macrociclicos adecuados para el tratamiento de infecciones viricas de la hepatitis c.
EP1753775B1 (de) *	2004-05-25	2012-12-26	Boehringer Ingelheim International GmbH	Verfahren zur herstellung von acyclischen hcv-protease-inhibitoren
JP4914348B2 (ja) *	2004-06-28	2012-04-11	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃ型肝炎インヒビターペプチド類似体
UY29016A1 (es) *	2004-07-20	2006-02-24	Boehringer Ingelheim Int	Analogos de dipeptidos inhibidores de la hepatitis c
JP4914355B2 (ja) *	2004-07-20	2012-04-11	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃ型肝炎インヒビターペプチド類似体
US7189844B2 (en)	2004-09-17	2007-03-13	Boehringer Ingelheim International Gmbh	Ring-closing metathesis process in supercritical fluid
DE102005002336A1 (de) *	2005-01-17	2006-07-20	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Durchführung von kontinuierlichen Olefin-Ringschluss-Metathesen in komprimiertem Kohlendioxid
US7323447B2 (en)	2005-02-08	2008-01-29	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
CN103172697A (zh)	2005-03-08	2013-06-26	贝林格尔.英格海姆国际有限公司	制备大环化合物的方法
US7592336B2 (en)	2005-05-10	2009-09-22	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7601686B2 (en)	2005-07-11	2009-10-13	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US20080200497A1 (en) *	2005-07-20	2008-08-21	Bailey Murray D	Hepatitis C Inhibitor Peptide Analogs
AR057456A1 (es)	2005-07-20	2007-12-05	Merck & Co Inc	Inhibidores de la proteasa ns3 del vhc
EP2305696A3 (de) *	2005-07-25	2011-10-12	Intermune, Inc.	Makrocyclische Inhibitoren der Replikation des Hepatitis-C-Virus
PE20070343A1 (es) *	2005-07-29	2007-05-12	Medivir Ab	Inhibidores macrociclicos del virus de la hepatitis c
PE20070210A1 (es) *	2005-07-29	2007-04-16	Tibotec Pharm Ltd	Compuestos macrociclicos como inhibidores del virus de hepatitis c
WO2007014922A1 (en) *	2005-07-29	2007-02-08	Tibotec Pharmaceuticals Ltd.	Macrocyclic inhibitors of hepatitis c virus
CN101233131B (zh) *	2005-07-29	2011-06-08	泰博特克药品有限公司	丙型肝炎病毒的大环抑制剂
ATE496042T1 (de)	2005-07-29	2011-02-15	Tibotec Pharm Ltd	Makrocyclische inhibitoren des hepatitis-c-virus
EP1910347A2 (de) *	2005-07-29	2008-04-16	Medivir Ab	Makrozyklische hepatitis-c-virus-inhibitoren
RU2436787C2 (ru) *	2005-07-29	2011-12-20	Тиботек Фармасьютикалз Лтд.	Макроциклические ингибиторы вируса гепатита с
BRPI0614637A2 (pt) *	2005-07-29	2011-04-12	Tibotec Pharm Ltd	inibidores macrocìclicos do vìrus da hepatite c
PE20070211A1 (es)	2005-07-29	2007-05-12	Medivir Ab	Compuestos macrociclicos como inhibidores del virus de hepatitis c
ES2401661T3 (es) *	2005-08-02	2013-04-23	Vertex Pharmaceuticals Incorporated	Inhibidores de serina proteasas
CA2618682C (en)	2005-08-12	2011-06-21	Boehringer Ingelheim International Gmbh	Viral polymerase inhibitors
US7964624B1 (en)	2005-08-26	2011-06-21	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases
AR055395A1 (es) *	2005-08-26	2007-08-22	Vertex Pharma	Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
EP1934243B1 (de) *	2005-09-09	2011-05-25	Boehringer Ingelheim International GmbH	Cyclisierendes metatheseverfahren zur herstellung von makrocyclischen peptiden
EA200801050A1 (ru)	2005-10-11	2008-12-30	Интермьюн, Инк.	Соединения и способы ингибирования репликации вирусного гепатита с
US7772183B2 (en)	2005-10-12	2010-08-10	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7741281B2 (en)	2005-11-03	2010-06-22	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7816348B2 (en)	2006-02-03	2010-10-19	Boehringer Ingelheim International Gmbh	Viral polymerase inhibitors
EP1991229A2 (de)	2006-02-27	2008-11-19	Vertex Pharmaceuticals Incorporated	Kokristalle und pharmazeutische zusammensetzungen damit
JP2009531315A (ja)	2006-03-16	2009-09-03	バーテックスファーマシューティカルズインコーポレイテッド	重水素化ｃ型肝炎プロテアーゼインヒビター
UY30437A1 (es)	2006-06-26	2008-01-31	Enanta Pharm Inc	Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
RU2008152171A (ru) *	2006-07-05	2010-08-10	Интермьюн, Инк. (Us)	Новые ингибиторы вирусной репликации гепатита с
WO2008008776A2 (en)	2006-07-11	2008-01-17	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
US7718612B2 (en) *	2007-08-02	2010-05-18	Enanta Pharmaceuticals, Inc.	Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
WO2008019477A1 (en)	2006-08-17	2008-02-21	Boehringer Ingelheim International Gmbh	Viral polymerase inhibitors
HRP20110193T1 (hr)	2006-10-10	2011-05-31	Medivir Ab	Inhibitor hcv nukleozida
US8343477B2 (en)	2006-11-01	2013-01-01	Bristol-Myers Squibb Company	Inhibitors of hepatitis C virus
US7772180B2 (en)	2006-11-09	2010-08-10	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7763584B2 (en)	2006-11-16	2010-07-27	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7888464B2 (en)	2006-11-16	2011-02-15	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8003604B2 (en)	2006-11-16	2011-08-23	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8575208B2 (en) *	2007-02-27	2013-11-05	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases
EA200970806A1 (ru) *	2007-02-27	2010-08-30	Вертекс Фармасьютикалз Инкорпорейтед	Сокристаллы и содержащие их фармацевтические композиции
CA2686546A1 (en)	2007-05-10	2008-11-20	Intermune, Inc.	Novel peptide inhibitors of hepatitis c virus replication
US20090005387A1 (en) *	2007-06-26	2009-01-01	Deqiang Niu	Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
WO2009018657A1 (en)	2007-08-03	2009-02-12	Boehringer Ingelheim International Gmbh	Viral polymerase inhibitors
EP2436682A1 (de)	2007-08-30	2012-04-04	Vertex Pharmceuticals Incorporated	Kokristalle und pharmazeutische Zusammensetzungen damit
US8419332B2 (en) *	2007-10-19	2013-04-16	Atlas Bolt & Screw Company Llc	Non-dimpling fastener
CA2708150A1 (en)	2007-12-05	2009-06-18	Enanta Pharmaceuticals, Inc.	Fluorinated tripeptide hcv serine protease inhibitors
EP2234977A4 (de)	2007-12-19	2011-04-13	Boehringer Ingelheim Int	Viren-polymerasehemmer
US8202996B2 (en)	2007-12-21	2012-06-19	Bristol-Myers Squibb Company	Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
RU2490272C2 (ru) *	2008-02-04	2013-08-20	Айденикс Фармасьютикалз, Инк.	Макроциклические ингибиторы серинпротеазы
US8163921B2 (en)	2008-04-16	2012-04-24	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
CN102046648A (zh)	2008-05-29	2011-05-04	百时美施贵宝公司	丙型肝炎病毒抑制剂
US7964560B2 (en)	2008-05-29	2011-06-21	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8207341B2 (en)	2008-09-04	2012-06-26	Bristol-Myers Squibb Company	Process or synthesizing substituted isoquinolines
UY32099A (es) *	2008-09-11	2010-04-30	Enanta Pharm Inc	Inhibidores macrocíclicos de serina proteasas de hepatitis c
AU2009293493B2 (en) *	2008-09-17	2014-09-18	Boehringer Ingelheim International Gmbh	Combination of HCV NS3 protease inhibitor with interferon and ribavirin
US8044087B2 (en)	2008-09-29	2011-10-25	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8563505B2 (en)	2008-09-29	2013-10-22	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8283310B2 (en)	2008-12-15	2012-10-09	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
KR20110116136A (ko)	2009-01-07	2011-10-25	싸이넥시스, 인크.	Ｈｃｖ 및 ｈｉｖ 감염의 치료에 사용하기 위한 사이클로스포린 유도체
TW201040181A (en)	2009-04-08	2010-11-16	Idenix Pharmaceuticals Inc	Macrocyclic serine protease inhibitors
CA2761650C (en)	2009-05-13	2015-05-26	Enanta Pharmaceuticals, Inc.	Macrocyclic compounds as hepatitis c virus inhibitors
US8232246B2 (en) *	2009-06-30	2012-07-31	Abbott Laboratories	Anti-viral compounds
PE20120322A1 (es) *	2009-07-07	2012-04-14	Boehringer Ingelheim Int	Composicion farmaceutica que comprende faldaprevir o una sal del mismo en un vehiculo auto-emulsionante
AR077712A1 (es)	2009-08-05	2011-09-14	Idenix Pharmaceuticals Inc	Inhibidores de serina proteasa macrociclica
US9193740B2 (en) *	2009-10-19	2015-11-24	Enanta Pharmaceuticals, Inc.	Bismacrocyclic compounds as hepatitis C virus inhibitors
KR20120106942A (ko)	2009-10-30	2012-09-27	베링거 인겔하임 인터내셔날 게엠베하	Ｂｉ２０１３３５, 인터페론 알파 및 리바비린을 포함하는 ｈｃｖ 병용 치료요법을 위한 투여 용법
TWI523658B (zh)	2010-09-21	2016-03-01	安塔製藥公司	巨環脯胺酸衍生之ｈｃｖ絲胺酸蛋白酶抑制劑
KR20140003521A (ko)	2010-12-30	2014-01-09	이난타 파마슈티칼스, 인코포레이티드	페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제
CN103534256B (zh)	2010-12-30	2016-08-10	益安药业	大环丙型肝炎丝氨酸蛋白酶抑制剂
TW201309690A (zh)	2011-02-10	2013-03-01	Idenix Pharmaceuticals Inc	巨環絲胺酸蛋白酶抑制劑，其醫藥組合物及其於治療ｈｃｖ感染之用途
US8957203B2 (en)	2011-05-05	2015-02-17	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US10201584B1 (en)	2011-05-17	2019-02-12	Abbvie Inc.	Compositions and methods for treating HCV
US8691757B2 (en)	2011-06-15	2014-04-08	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
BR112015007887A2 (pt)	2012-10-08	2017-07-04	Abbvie Inc	compostos úteis para produzir inibidores hcv protease
JP6154474B2 (ja)	2012-10-19	2017-06-28	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	Ｃ型肝炎ウイルス阻害剤
WO2014071007A1 (en)	2012-11-02	2014-05-08	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
EP2914613B1 (de)	2012-11-02	2017-11-22	Bristol-Myers Squibb Company	Inhibitoren des hepatitis-c-virus
US9643999B2 (en)	2012-11-02	2017-05-09	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
EP2914614B1 (de)	2012-11-05	2017-08-16	Bristol-Myers Squibb Company	Inhibitoren des hepatitis-c-virus
EP2964664B1 (de)	2013-03-07	2017-01-11	Bristol-Myers Squibb Company	Hemmer des hepatitis-c-virus
WO2015103490A1 (en)	2014-01-03	2015-07-09	Abbvie, Inc.	Solid antiviral dosage forms
US12083099B2 (en)	2020-10-28	2024-09-10	Accencio LLC	Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5824784A (en) *	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
US6159938A (en) *	1994-11-21	2000-12-12	Cortech, Inc.	Serine protease inhibitors comprising α-keto heterocycles
AU2933797A (en)	1996-05-10	1997-12-05	Schering Corporation	Synthetic inhibitors of hepatitis c virus ns3 protease
NZ335276A (en)	1996-10-18	2000-09-29	Vertex Pharma	Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease
GB9623908D0 (en)	1996-11-18	1997-01-08	Hoffmann La Roche	Amino acid derivatives
WO1998046597A1 (en)	1997-04-14	1998-10-22	Emory University	Serine protease inhibitors
GB9707659D0 (en)	1997-04-16	1997-06-04	Peptide Therapeutics Ltd	Hepatitis C NS3 Protease inhibitors
JPH10298151A (ja)	1997-04-30	1998-11-10	Japan Energy Corp	Ｃ型肝炎ウイルスプロテアーゼ阻害剤
JPH1135478A (ja)	1997-07-17	1999-02-09	Soyaku Gijutsu Kenkyusho:Kk	キク科植物の有機抽出物を含有する抗ｃ型肝炎ウイルス剤及びプロテアーゼｎｓ３の特異的阻害剤
IL134232A0 (en)	1997-08-11	2001-04-30	Boehringer Ingelheim Ca Ltd	Hepatitis c inhibitor peptides
PT1012180E (pt)	1997-08-11	2005-04-29	Boehringer Ingelheim Ca Ltd	Analogos de peptidos inibidores da hepatite c
JPH11127861A (ja)	1997-10-29	1999-05-18	Japan Energy Corp	Ｃ型肝炎ウイルス由来のセリンプロテアーゼに対する中和抗体部分ペプチド
JP3612551B2 (ja)	1997-11-07	2005-01-19	独立行政法人産業技術総合研究所	Ｃ型肝炎ウイルスのｎｓ３プロテアーゼを阻害するｒｎａ分子
IT1299134B1 (it)	1998-02-02	2000-02-29	Angeletti P Ist Richerche Bio	Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi
GB9806815D0 (en)	1998-03-30	1998-05-27	Hoffmann La Roche	Amino acid derivatives
AU3376699A (en)	1998-03-31	1999-10-18	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
JPH11292840A (ja)	1998-04-06	1999-10-26	Soyaku Gijutsu Kenkyusho:Kk	ノルスタチン誘導体又はその塩
GB9809664D0 (en) *	1998-05-06	1998-07-01	Hoffmann La Roche	a-Ketoamide derivatives
GB9812523D0 (en)	1998-06-10	1998-08-05	Angeletti P Ist Richerche Bio	Peptide inhibitors of hepatitis c virus ns3 protease
CA2338490A1 (en)	1998-07-27	2000-02-10	Sergio Altamura	Diketoacid-derivatives as inhibitors of polymerases
US6323180B1 (en)	1998-08-10	2001-11-27	Boehringer Ingelheim (Canada) Ltd	Hepatitis C inhibitor tri-peptides
AR022061A1 (es)	1998-08-10	2002-09-04	Boehringer Ingelheim Ca Ltd	Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
WO2000020400A1 (en)	1998-10-05	2000-04-13	Axys Pharmaceuticals, Inc.	Novel compounds and compositions for treating hepatitis c infections
GB9825946D0 (en)	1998-11-26	1999-01-20	Angeletti P Ist Richerche Bio	Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease
UA74546C2 (en) *	1999-04-06	2006-01-16	Boehringer Ingelheim Ca Ltd	Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6608027B1 (en) *	1999-04-06	2003-08-19	Boehringer Ingelheim (Canada) Ltd	Macrocyclic peptides active against the hepatitis C virus
WO2001002424A2 (en)	1999-07-07	2001-01-11	Du Pont Pharmaceuticals Company	Peptide boronic acid inhibitors of hepatitis c virus protease
CA2376961A1 (en)	1999-07-26	2001-02-01	Bristol-Myers Squibb Pharma Company	Lactam inhibitors of hepatitis c virus ns3 protease
AU7511800A (en)	1999-08-30	2001-03-26	K.U. Leuven Research And Development	Novel target for antiparasitic agents and inhibitors thereof
JP2001103993A (ja)	1999-10-05	2001-04-17	Japan Energy Corp	環状ペプチド及びセリンプロテアーゼ阻害剤
GB9925955D0 (en)	1999-11-02	1999-12-29	Angeletti P Ist Richerche Bio	Hcv n33 protease inhibitors
AU2055301A (en)	1999-12-03	2001-06-12	Bristol-Myers Squibb Pharma Company	Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
CZ20013424A3 (cs)	1999-12-27	2002-02-13	Japan Tobacco Inc.	Sloučeniny s fúzovanými kruhy a jejich pouľití jako léčiva
WO2001058929A1 (en)	2000-02-08	2001-08-16	Schering Corporation	Azapeptides useful in the treatment of hepatitis c
WO2001064678A2 (en)	2000-02-29	2001-09-07	Bristol-Myers Squibb Pharma Company	Inhibitors of hepatitis c virus ns3 protease
AU2001251165A1 (en)	2000-04-03	2001-10-15	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
HK1047947A1 (zh)	2000-04-05	2003-03-14	Schering Corporation	包含n-环状p2部分的丙型肝炎病毒的大环ns3-丝氨酸蛋白酶抑制剂
AU2001253621A1 (en)	2000-04-19	2001-11-07	Schering Corporation	Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties
WO2001085172A1 (en)	2000-05-10	2001-11-15	Smithkline Beecham Corporation	Novel anti-infectives
MY164523A (en)	2000-05-23	2017-12-29	Univ Degli Studi Cagliari	Methods and compositions for treating hepatitis c virus
GB0017676D0 (en)	2000-07-19	2000-09-06	Angeletti P Ist Richerche Bio	Inhibitors of viral polymerase
US7012066B2 (en)	2000-07-21	2006-03-14	Schering Corporation	Peptides as NS3-serine protease inhibitors of hepatitis C virus
AR029851A1 (es)	2000-07-21	2003-07-16	Dendreon Corp	Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
AR034127A1 (es)	2000-07-21	2004-02-04	Schering Corp	Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
SK742003A3 (en)	2000-07-21	2003-06-03	Schering Corp	Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
US20020068702A1 (en)	2000-07-21	2002-06-06	Marguerita Lim-Wilby	Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
SV2003000617A (es)	2000-08-31	2003-01-13	Lilly Co Eli	Inhibidores de la proteasa peptidomimetica ref. x-14912m
MXPA03004299A (es) *	2000-11-20	2004-02-12	Bristol Myers Squibb Co	Inhibidores de tripeptido de hepatitis c.
MXPA03006514A (es)	2001-01-22	2004-12-02	Merck & Co Inc	Derivados de nucleosidos como inhibidores de polimerasa de acido ribonucleico viral dependiente de acido ribonucleico.
WO2002069903A2 (en)	2001-03-06	2002-09-12	Biocryst Pharmaceuticals, Inc.	Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
GB0107924D0 (en)	2001-03-29	2001-05-23	Angeletti P Ist Richerche Bio	Inhibitor of hepatitis C virus NS3 protease
EP1256628A3 (de)	2001-05-10	2003-03-19	Agouron Pharmaceuticals, Inc.	Hepatitis C Virus (HCV) NS5B RNA Polymerase und davon abgeleitete Mutanten
AR036081A1 (es)	2001-06-07	2004-08-11	Smithkline Beecham Corp	Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
EP2363396A1 (de)	2001-06-11	2011-09-07	Virochem Pharma Inc.	Thiophenderivate als antivirale Mittel gegen Flavivirus-Infektion
EP1395571A1 (de)	2001-06-11	2004-03-10	Shire Biochem Inc.	Verbindungen und methoden zum behandeln oder vorbeugen von flavivirus infektionen
AR035543A1 (es)	2001-06-26	2004-06-16	Japan Tobacco Inc	Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
CA2448737C (en)	2001-07-20	2010-06-01	Boehringer Ingelheim (Canada) Ltd.	Viral polymerase inhibitors
EP2335700A1 (de)	2001-07-25	2011-06-22	Boehringer Ingelheim (Canada) Ltd.	Hepatitis C Virus Polymerase Inhibitoren mit heterobicylischer Struktur
US20030134853A1 (en)	2001-09-26	2003-07-17	Priestley Eldon Scott	Compounds useful for treating hepatitis C virus
US6867185B2 (en) *	2001-12-20	2005-03-15	Bristol-Myers Squibb Company	Inhibitors of hepatitis C virus
US7119072B2 (en) *	2002-01-30	2006-10-10	Boehringer Ingelheim (Canada) Ltd.	Macrocyclic peptides active against the hepatitis C virus
CA2369711A1 (en)	2002-01-30	2003-07-30	Boehringer Ingelheim (Canada) Ltd.	Macrocyclic peptides active against the hepatitis c virus
AU2003248535A1 (en)	2002-05-20	2003-12-12	Bristol-Myers Squibb Company	Heterocyclicsulfonamide hepatitis c virus inhibitors
US20040138109A1 (en) *	2002-09-30	2004-07-15	Boehringer Ingelheim Pharmaceuticals, Inc.	Potent inhibitor of HCV serine protease
US20050075279A1 (en)	2002-10-25	2005-04-07	Boehringer Ingelheim International Gmbh	Macrocyclic peptides active against the hepatitis C virus
US7223785B2 (en) *	2003-01-22	2007-05-29	Boehringer Ingelheim International Gmbh	Viral polymerase inhibitors
ATE422895T1 (de) *	2003-04-16	2009-03-15	Bristol Myers Squibb Co	Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
CL2004001161A1 (es) *	2003-05-21	2005-04-08	Boehringer Ingelheim Int	Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
EP1673385B1 (de) *	2003-09-22	2011-03-02	Boehringer Ingelheim International GmbH	Makrozyklische peptide mit wirkung gegen das hepatitis-c-virus
CN1922174A (zh) *	2004-02-20	2007-02-28	贝林格尔·英格海姆国际有限公司	病毒聚合酶抑制剂
UY29017A1 (es) *	2004-07-16	2006-02-24	Boehringer Ingelheim Int	Inhibidores de polimerasa viral
US7939545B2 (en) *	2006-05-16	2011-05-10	Boehringer Ingelheim International Gmbh	Inhibitors of human immunodeficiency virus replication

2003
- 2003-10-16 US US10/686,755 patent/US20050075279A1/en not_active Abandoned
- 2003-10-20 WO PCT/CA2003/001604 patent/WO2004037855A1/en not_active Ceased
- 2003-10-20 JP JP2005501488A patent/JP4398424B2/ja not_active Expired - Fee Related
- 2003-10-20 EP EP03809217A patent/EP1558632B1/de not_active Expired - Lifetime
- 2003-10-20 AU AU2003275826A patent/AU2003275826A1/en not_active Abandoned
- 2003-10-20 AT AT03809217T patent/ATE443713T1/de active
- 2003-10-20 CA CA2498572A patent/CA2498572C/en not_active Expired - Fee Related
- 2003-10-20 DE DE60329408T patent/DE60329408D1/de not_active Expired - Lifetime
- 2003-10-20 ES ES03809217T patent/ES2330932T3/es not_active Expired - Lifetime
2005
- 2005-12-10 US US11/298,443 patent/US7504378B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2498572C (en)	2011-08-23
JP2006517915A (ja)	2006-08-03
EP1558632B1 (de)	2009-09-23
AU2003275826A1 (en)	2004-05-13
CA2498572A1 (en)	2004-05-06
EP1558632A1 (de)	2005-08-03
US20050075279A1 (en)	2005-04-07
WO2004037855A1 (en)	2004-05-06
US7504378B2 (en)	2009-03-17
ES2330932T3 (es)	2009-12-17
JP4398424B2 (ja)	2010-01-13
US20060089300A1 (en)	2006-04-27
DE60329408D1 (de)	2009-11-05

Legal Events

Date

Code

Title

Description

2010-02-15

UEP

Publication of translation of european patent specification

Ref document number: 1558632

Country of ref document: EP

Publication	Publication Date	Title
DE60329408D1 (de)	2009-11-05	Makrozyklische peptide mit wirkung gegen das hepatitis-c-virus
WO2003064455A3 (en)	2004-02-05	Macrocyclic peptides active against the hepatitis c virus
MY127791A (en)	2006-12-29	Hepatitis c inhibitor tri-peptides
ATE486889T1 (de)	2010-11-15	Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
DK1481000T3 (da)	2010-09-06	Nye peptider som NS3-serin-proteasehæmmere af hepatitis C-virus
EP1771454A4 (de)	2009-05-13	Peptidanaloga als hepatitis c-hemmer
NO20061767L (no)	2006-06-16	Makrosykliske peptider som er aktive mot hepatitt C virus
AR038382A1 (es)	2005-01-12	Compuesto inhibidor de la hepatitis c
CY2011020I1 (el)	2016-12-14	Νεα πεπτιδια ως αναστολεις πρωτεασης ns3-σερινης του ιου ηπατιτιδας c
CY1109748T1 (el)	2014-09-10	Κινοξαλινυλ μακροκυκλικοι αναστολεις πρωτεασης σερινης ηπατιτιδας c
PE20050940A1 (es)	2005-11-08	Nuevos inhibidores de la ns3/ns4a serina proteasa del virus de la hepatitis c
EP1303487A4 (de)	2005-11-23	Neue peptide als ns3-serin protease inhibitoren des hepatitis c virus
WO2004113365A3 (en)	2005-07-21	Hepatitis c serine protease tri-peptide inhibitors
ZA200607048B (en)	2008-06-25	Novel ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus
WO2004014852A3 (en)	2004-04-22	Iminothiazolidinones as inhibitors of hcv replication
EA200501689A1 (ru)	2006-06-30	Соединения в качестве ингибиторов вируса гепатита c
DE602005010607D1 (de)	2008-12-04	Zyklosporinanalog
CA2474156A1 (en)	2003-08-07	Tripeptides having a hydroxyproline ether of a substituted quinoline for the inhibition of ns3 (hepatitis c)
HK1096657A (en)	2007-06-08	Novel ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus
TH62682A (th)	2004-06-30	ไทร-เพพไทด์ตัวยับยั้งตับอักเสบ c